Integer Holdings Corporation (ITGR)
Healthcare · Medical Devices · NYSE
Integer Holdings Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08B | $1.14B | $1.22B | $1.26B | $1.07B | $1.22B | $1.38B | $1.60B | $1.72B | $1.85B |
| Gross profit | $337.68M | $354.01M | $362.67M | $355.01M | $285.71M | $336.97M | $345.76M | $409.89M | $459.01M | $500.39M |
| Net income | $5.96M | $66.68M | $167.96M | $96.34M | $77.26M | $96.81M | $66.38M | $90.65M | $119.90M | $102.81M |
| Net margin | 0.6% | 5.9% | 13.8% | 7.7% | 7.2% | 7.9% | 4.8% | 5.7% | 7.0% | 5.5% |
Source: Integer Holdings Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Integer Holdings Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ITGR in your portfolio →
About Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Integer Holdings Corporation — frequently asked questions
What is Integer Holdings Corporation's revenue?
Integer Holdings Corporation (ITGR) reported revenue of $1.85B for fiscal year 2025, up 8.0% from the prior year, according to its SEC filings.
Is Integer Holdings Corporation profitable?
Yes. ITGR earned net income of $102.81M in fiscal 2025, a net margin of 5.5%.
What is ITGR's P/E ratio?
Integer Holdings Corporation trades at a price-to-earnings ratio of about 22.9 based on the latest data in our nightly-refreshed cache.
How fast is Integer Holdings Corporation growing?
ITGR's revenue grew at roughly 11.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Integer Holdings Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.